On October 22, 2024, Song Ruilin, Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), was invited to serve as Honorary Chairman of the HK Bio-Med Innotech Association (HKBMIA). This appointment underscores the close collaboration and mutual support between the two associations in advancing the pharmaceutical industry and signifies a new milestone in their partnership.

Dr. Song has long been dedicated to advancing regulatory globalization and fostering innovation in the pharmaceutical industry. As a seasoned expert in China's healthcare and pharmaceutical sector, and a key advocate for pharmaceutical innovation and reform, he has made significant contributions to industry development. His profound insights and strong advocacy for the development of Hong Kong and the Guangdong-Hong Kong-Macao Greater Bay Area (Greater Bay Area)’s pharmaceutical industry have laid a solid foundation for further collaboration between the regions.

Dr. Song noted that Hong Kong, as the most "China-centric" international city and the most international city in China, serves as a vital gateway in the nation’s economic development. Looking ahead, he expressed his commitment to working closely with HKBMIA to leverage Hong Kong’s strengths as a global financial hub and logistics center. Together, they aim to promote the development of the Greater Bay Area’s pharmaceutical industry and foster deeper cooperation with mainland China’s pharmaceutical sector, contributing to the advancement of pharmaceutical innovation in China.

The current Honorary Chairmen of HKBMIA are:

1. Professor Nancy Ip, SBS, BBS, MH, JP, President of the Hong Kong University of Science and Technology and Hong Kong Deputy of the National People's Congress

2. Professor Dennis Lo, SBS, JP,  Vice-Chancellor and President Designate of the Chinese University of Hong Kong

3. Professor Chak-sing Lau, BBS, JP, Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at the University of Hong Kong

Since its establishment in 2017, under the leadership of President Lo Yuk Lam, HKBMIA has been committed to advancing Hong Kong’s pharmaceutical industry. Notably, it has played a critical role in advocating for improvements in Hong Kong’s legal framework and regulatory system for pharmaceuticals. Simultaneously, HKBMIA has maintained a long-term, in-depth collaboration with PhIRDA, jointly promoting the coordinated development of the pharmaceutical industries in the Greater Bay Area and mainland China.

Looking forward, PhIRDA will continue to deepen its collaboration with HKBMIA, focusing on areas such as policy innovation, technology transfer, and talent development. By serving as a bridge, both associations aim to contribute to the prosperity of Hong Kong’s pharmaceutical industry and the sustainable development of pharmaceutical innovation in mainland China.

About HKBMIA
The HK Bio-Med Innotech Association (HKBMIA) is committed to creating an innovative and globally recognized platform for the biotechnology and pharmaceutical technology industry in Hong Kong.

Our proactive approach involves the introduction of outstanding overseas biotechnology and pharmaceutical innovation projects and industries. We provide comprehensive assistance in various areas, encompassing the formulation of industrialization and business development plans, financing and listing support, corporate governance and auditing, research and development technology, intellectual property protection, valuation, policy and regulatory matters, as well as clinical trial design and planning. These endeavors aim to facilitate entry into the domestic market and foster growth in the industry.